Please use this identifier to cite or link to this item:
|Title:||Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [c-11]befloxatone.|
Positron computed tomography
|Publisher:||Lippincott, Williams & Wilkins|
|Citation:||Leroy, C., Bragulat, V., Berlin, I., Gregoire, M. C., Bottlaender, M., Roumenov, D., Dolle, F., Bourgeois, S., Penttilae, J., Artiges, E., Martinot, J. L., & Trichard, C. (2009). Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [c-11]befloxatone. Journal of Clinical Psychopharmacology, 29(1), 86-88. doi:10.1097/JCP.0b013e31819e98f|
|Abstract:||The inhibition of cerebral monoamine oxidases (MAOs) by cigarette smoke components could participate to the tobacco addiction. However, the actual extent of this inhibition in vivo in smokers is still poorly known. We investigated cerebral MAO-A availability in 7 tobacco-dependent subjects and 6 healthy nonsmokers, using positron emission tomography (PET) and the MAO-A selective radioligand [11C]befloxatone. In comparison to nonsmokers, smokers showed a significant overall reduction of [11C]befloxatone binding potential (BP) in cortical areas (average reduction, -60%) and a similar trend in caudate and thalamus (-40%). Our findings confirm a widespread inhibition of cerebral MAO-A in smokers. This mechanism may contribute to tobacco addiction and for a possible mood-modulating effect of tobacco. © 2009, Lippincott, Williams & Wilkins|
|Gov't Doc #:||1527|
|Appears in Collections:||Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.